First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: A 3-month efficacy analysis stratified by initial intraocular pressure

BMC Ophthalmology

Volumn 10, Issue 1, 2010, Pages

  Denis, Philippe ^a   Baudouin, Christophe ^b   Bron, Alain ^c   Nordmann, Jean Philippe ^b   Renard, Jean Paul ^d   Rouland, Jean François ^e   Sellem, Eric ^f   Amrane, Mourad ^g  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^c HÔPITAL DU BOCAGE   (France)

^d University of Paris Descartes   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f Centre Ophtalmologique Kleber   (France)

^g NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; LATANOPROST; PROSTAGLANDIN F;

AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONJUNCTIVA; DRUG ADMINISTRATION; DRUG EFFECT; DRUG INSTILLATION; EYE; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PAIN; PATHOPHYSIOLOGY; PHASE 4 CLINICAL TRIAL; PROGNOSIS; TREATMENT OUTCOME; VASCULARIZATION;

AGED; ANTIHYPERTENSIVE AGENTS; CONJUNCTIVA; DRUG ADMINISTRATION SCHEDULE; EYE; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; HYPEREMIA; INSTILLATION, DRUG; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PAIN; PROGNOSIS; PROSTAGLANDINS F, SYNTHETIC; TREATMENT OUTCOME;

EID: 77949699210     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-10-4     Document Type: Article

References (39)

1. Global data on visual impairment in the year 2002. S Resnikoff D Pascolini D Etya'ale I Kocur R Pararajasegaram GP Pokharel SP Mariotti, Bull World Health Organ 2004 82 844 851 15640920
2. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. DS Friedman MR Wilson JM Liebmann RD Fechtner RN Weinreb, Am J Ophthalmol 2004 138 3 Suppl 19 31 15364049
3. Compliance with topical timolol treatment. MA Kass M Gordon RE Morley Jr DW Meltzer JJ Goldberg, Am J Ophthalmol 1987 103 188 193 3812621
4. Predictors of long-term progression in the early manifest glaucoma trial. MC Leske A Heijl L Hyman B Bengtsson L Dong Z Yang EMGT Group, Ophthalmology 2007 114 1965 1972 10.1016/j.ophtha.2007.03.016 17628686
5. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators, Am J Ophthalmol 2000 130 429 440 10.1016/S0002-9394(00)00538-9 11024415
6. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. A Heijl MC Leske B Bengtsson L Hyman B Bengtsson M Hussein Early Manifest Glaucoma Trial Group, Arch Ophthalmol 2002 120 1268 1279 12365904
7. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. MC Leske A Heijl M Hussein B Bengtsson L Hyman E Komaroff Early Manifest Glaucoma Trial Group, Arch Ophthalmol 2003 121 48 56 12523884
8. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. PR Lichter DC Musch BW Gillespie KE Guire NK Janz PA Wren RP Mills CIGTS Study Group, Ophthalmology 2001 108 1943 1953 10.1016/S0161-6420(01)00873-9 11713061
9. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. A Alm J Stjernschantz, Ophthalmology 1995 102 1743 1752 9098273
10. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. CB Camras, Ophthalmology 1996 103 138 147 8628544
11. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. P Watson J Stjernschantz, Ophthalmology 1996 103 126 137 8628543
12. Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: the intervisit intraocular pressure range. R Varma LJ Hwang JW Grunden GW Bean MB Sultan, Am J Ophthalmol 2009 148 221 226 10.1016/j.ajo.2009.02.035 19427617
13. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. K Hedman LI Larsson, Surv Ophthalmol 2002 47 Suppl 1 77 89 10.1016/S0039-6257(02)00310-7 12204703
14. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group, Am J Ophthalmol 1998 126 487 497 10.1016/S0002-9394(98)00223-2 9780093
15. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. RK Parrish P Palmberg WP Sheu XLT Study Group, Am J Ophthalmol 2003 135 688 703 10.1016/S0002-9394(03)00098-9 12719078
16. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. N Orzalesi L Rossetti A Bottoli P Fogagnolo, Ophthalmology 2006 113 239 246 10.1016/j.ophtha.2005.10.045 16458092
17. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. N Yildirim A Sahin S Gultekin, J Glaucoma 2008 17 36 39 10.1097/IJG. 0b013e318133fb70 18303382
18. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. A Bayer W Weiler U Oeverhaus FE Skrotzki WC Stewart the XPLORE Observation Group, J Ocul Pharmacol Ther 2004 20 470 478 10.1089/jop.2004.20.470 15684807
19. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. I Goldberg XY Li P Selaru D Paggiarino, Eur J Ophthalmol 2008 18 408 416 18465724
20. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. K Hedman A Alm, Eur J Ophthalmol 2000 10 95 104 10887918
21. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma. A Ang MA Reddy L Shepstone DC Broadway, Br J Ophthalmol 2004 88 630 634 10.1136/bjo.2003.020826 15090413
22. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. AH Rulo EL Greve HC Geijssen PF Hoyng, Ophthalmology 1996 103 1276 1282 8764799
23. Basic and Clinical Biostatistics. B Dawson-Saunders RB Trapp, Norwalk, CT: Appleton & Lange 1990
24. European Glaucoma Society Terminology and Guidelines for Glaucoma. Savona, Italy: DOGMA II 2008 http://www.eugs.org/eng/default.asp Accessed: March 12, 2009
25. Lumigan [package insert], Irvine, Calif: Allergan, Inc 2006
26. Travatan [package insert], Fort Worth, Tex: Alcon Laboratories, Inc 2005
27. Xalatan [package insert], New York, NY: Pfizer Inc 2003
28. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. MA Kass DK Heuer EJ Higginbotham CA Johnson JL Keltner JP Miller RK Parrish MR Wilson MO Gordon, Arch Ophthalmol 2002 120 701 713 12049574
29. The logic behind target intraocular pressure. AL Coleman J Caprioli, Am J Ophthalmol 2009 147 379 380 10.1016/j.ajo.2008.10.027 19217951
30. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. CM Olthoff JS Schouten BW van de Borne CA Webers, Ophthalmology 2005 112 953 961 10.1016/j.ophtha.2004.12.035 15885795
31. Treatment for glaucoma: adherence by the elderly. JH Gurwitz RJ Glynn M Monane DE Everitt D Gilden N Smith J Avorn, Am J Public Health 1993 83 711 716 10.2105/AJPH.83.5.711 8484454
32. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. AL Robin GD Novack DW Covert RS Crockett TS Marcic, Am J Ophthalmol 2007 144 533 540 10.1016/j.ajo.2007.06.012 17686450
33. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. M Krousel-Wood S Thomas P Muntner D Morisky, Curr Opin Cardiol 2004 19 357 362 10.1097/01.hco.0000126978. 03828.9e 15218396
34. On white-coat effects and the electronic monitoring of compliance. AR Feinstein, Arch Intern Med 1990 150 1377 1378 10.1001/archinte.150.7.1377 2369237
35. Persistence and adherence with topical glaucoma therapy. BL Nordstrom DS Friedman E Mozaffari HA Quigley AM Walker, Am J Ophthalmol 2005 140 598 606 16226511
36. Patient persistency with pharmacotherapy in the management of glaucoma. G Reardon GF Schwartz E Mozaffari, Eur J Ophthalmol 2003 13 Suppl 4 44 52 12948052
37. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. G Reardon GF Schwartz E Mozaffari, Clin Ther 2003 25 1172 1185 10.1016/S0149-2918(03)80074-7 12809964
38. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. GF Schwartz G Reardon E Mozaffari, Am J Ophthalmol 2004 137 1 Suppl 13 16 10.1016/j.ajo.2003.10.034 14697910
39. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: change in prescription patterns and patient persistence. TJ Zimmerman SR Hahn L Gelb H Tan EE Kim, J Ocul Pharmacol Ther 2009 25 145 152 10.1089/jop.2008.0072 19284321